Market Overview

US Stock Futures Fall Ahead Of Federal Budget

Related ADSK
The 5 Most Influential Companies In 3D Printing
Fast Money Halftime Report Final Trade From August 18
Tech Sector Lags as EMC, Juniper Sink (Fox Business)
Related SPEX
Spherix Announces First Trial of Nortel Patents Since Bankruptcy Scheduled vs Verizon for Q1 2015
Morning Market Movers

Pre-open movers

US stock futures dropped in early pre-market trade, ahead of jobs data. The US Treasury monthly budget report for December will be released at 2:00 p.m. ET. Futures for the Dow Jones Industrial Average tumbled 29 points to 16,352.00, while the Standard & Poor's 500 index futures dropped 5.20 points to 1,832.50. Futures for the Nasdaq 100 index fell 10.25 points to 3,551.25.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index surging 0.59%, London's FTSE 100 index dropping 0.03% and STOXX Europe 600 Index climbing 0.14%. German DAX 30 index rose 0.15% and French CAC 40 Index surged 0.10%. Italian industrial production climbed by 0.3% in November from October.

Asian markets ended mostly higher today. China's Shanghai Composite fell 0.19%, Hong Kong's Hang Seng Index climbed 0.19% and India's BSE Sensex rose 1.95%.

Broker Recommendation

Analysts at Morgan Stanley upgraded Autodesk (NASDAQ: ADSK) from “equal-weight” to “overweight.” The target price for Autodesk is set to $60.

Autodesk's shares closed at $51.47 on Friday.

Breaking news

  • Spherix (NASDAQ: SPEX) announced today a second settlement and license agreement under the CompuFill patents acquired in September 2013. To read the full news, click here.
  • JinkoSolar (NYSE: JKS) today announced that its Board of Directors has authorized the exploration of strategic alternatives with respect to JinkoSolar's downstream solar PV project business. To read the full news, click here.
  • AT&T (NYSE: T) today announced that the company will hire workers for 116 jobs in Kentucky, including 34 new jobs. To read the full news, click here.
  • Genzyme, a Sanofi company (NYSE: SNY), and Alnylam Pharmaceuticals (NASDAQ: ALNY) announced today that they have significantly expanded their strategic agreement to develop and commercialize treatments for rare genetic diseases. To read the full news, click here.

Posted-In: Morgan Stanley US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

 

Related Articles (ADSK + ALNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional